Hospital Clínica Universitario Virgen de la Arrixaca (SPAIN) Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2018
NCT03468465
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hospital Clínica Universitario Virgen de la Arrixaca (SPAIN) | Hospital Clínico Universitario Virgen de la Arrixaca

Active Ingredients

Drugs in Phase 4 Trials (1)

solifenacin (vesicare) (1 trial)

Drugs in Phase 3 Trials (2)

colchicine (colbenemid) (1 trial)

dapagliflozin (farxiga) (1 trial)

Drugs in Phase 2 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperkinesis (Phase 4)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Urinary Bladder, Overactive (Phase 4)

Urinary Incontinence (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4